GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (FRA:HDP1) » Definitions » EV-to-Revenue

Arrowhead Pharmaceuticals (FRA:HDP1) EV-to-Revenue : 75.40 (As of May. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Arrowhead Pharmaceuticals's enterprise value is €2,484.12 Mil. Arrowhead Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €32.95 Mil. Therefore, Arrowhead Pharmaceuticals's EV-to-Revenue for today is 75.40.

The historical rank and industry rank for Arrowhead Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:HDP1' s EV-to-Revenue Range Over the Past 10 Years
Min: -17.01   Med: 43.88   Max: 4865.36
Current: 75.72

During the past 13 years, the highest EV-to-Revenue of Arrowhead Pharmaceuticals was 4865.36. The lowest was -17.01. And the median was 43.88.

FRA:HDP1's EV-to-Revenue is ranked worse than
81.04% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs FRA:HDP1: 75.72

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Arrowhead Pharmaceuticals's stock price is €22.65. Arrowhead Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.31. Therefore, Arrowhead Pharmaceuticals's PS Ratio for today is 73.78.


Arrowhead Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Arrowhead Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals EV-to-Revenue Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.41 46.75 44.62 13.27 10.85

Arrowhead Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.56 13.53 10.85 17.61 89.01

Competitive Comparison of Arrowhead Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's EV-to-Revenue falls into.



Arrowhead Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Arrowhead Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2484.121/32.945
=75.40

Arrowhead Pharmaceuticals's current Enterprise Value is €2,484.12 Mil.
Arrowhead Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €32.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arrowhead Pharmaceuticals  (FRA:HDP1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Arrowhead Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=22.65/0.307
=73.78

Arrowhead Pharmaceuticals's share price for today is €22.65.
Arrowhead Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.31.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arrowhead Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (FRA:HDP1) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (FRA:HDP1) Headlines

No Headlines